The federal agency introduced Elsa last month, boasting about the AI tool's ability to increase efficiency at the FDA.

The FDA is still on track to meet its user fee targets despite a higher-than-normal vacancy rate among scientific reviewers.

Loss of support staff has slowed critical investigations of drug manufacturers. Little relief has materialized.

The investigative unit, which looks into potential safety issues with drugs, vaccines, medical devices, and other products, has had a retention problem for years. Inspectors leave so often that, even ...

WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...

Cuts at the FDA are slowing inspections of overseas drug manufacturers, prompting concerns from former and current employees that medication safety could be at risk, ProPublica reported July 7. Dozens ...

Even before the layoffs, the FDA's investigative force struggled to monitor drug-making factories in countries that include India and China, particularly during the COVID-19 pandemic, raising ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

Dr. George Tidmarsh, a Stanford pediatrics adjunct professor and former pharmaceutical executive, is FDA Commissioner Marty ...

Trump administration officials have defended the mass dismissals, saying they are overdue and necessary to make the ...

The steady erosion of experienced staff is slowly compromising FDA work and low morale is pushing more workers to the exits ...